A phase I trial of PS-341 [bortezomib] in combination with topotecan in advanced solid tumor malignancies
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Bortezomib (Primary) ; Topotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 22 Sep 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 22 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2010 Planned end date changed from 1 Oct 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.